CXCL12 Neutralizing Antibody as a Promising Treatment for Hair Loss in Androgenic Alopecia and Alopecia Areata
노바스템
2024-04-08
조회수 769
Research has unveiled CXCL12's crucial involvement in hair cycle regulation, highlighting its elevated expression in dermal fibroblasts (DFs) during catagen and telogen phases. In androgenic alopecia (AGA) and alopecia areata (AA), CXCL12 expression is significantly increased, contributing to hair loss. This study focuses on the effectiveness of a CXCL12 neutralizing antibody (αCXCL12) in mouse models of AGA and AA. In AGA models, CXCL12 is upregulated in DFs, and αCXCL12 injections lead to notable hair growth, contradicting the androgen-induced hair damage. Androgens increase CXCL12 secretion through the androgen receptor (AR), affecting dermal papilla cells (DPCs) and inducing hair loss. Similarly, in AA models, CXCL12 expression rises, with αCXCL12 injections significantly inhibiting hair loss and reducing CD8+ MHC-I+ and MHC-II+ cell numbers in the skin. This suggests that CXCL12 plays a role in the progression of both AGA and AA, making αCXCL12 a promising candidate for hair loss treatment.
The findings offer a novel pathway for enhancing stem cell therapy efficacy, particularly for Novastem's treatments targeting AGA and AA. By modulating the CXCL12/CXCR4 axis, it's possible to improve stem cell recruitment and function at the injury site, potentially offering better outcomes for patients suffering from these hair loss conditions. This research aligns with the broader goals of regenerative medicine, seeking innovative solutions for conditions lacking effective treatments.
αCXCL12 significantly promotes hair growth in AGA and inhibits hair loss in AA, suggesting its potential as a therapeutic agent.
The treatment modulates the CXCL12/CXCR4 axis, crucial for stem cell migration and inflammation response, indicating a dual mechanism of action.
This approach could revolutionize the treatment of hair loss conditions, offering a new hope for patients with AGA and AA.
Research has unveiled CXCL12's crucial involvement in hair cycle regulation, highlighting its elevated expression in dermal fibroblasts (DFs) during catagen and telogen phases. In androgenic alopecia (AGA) and alopecia areata (AA), CXCL12 expression is significantly increased, contributing to hair loss. This study focuses on the effectiveness of a CXCL12 neutralizing antibody (αCXCL12) in mouse models of AGA and AA. In AGA models, CXCL12 is upregulated in DFs, and αCXCL12 injections lead to notable hair growth, contradicting the androgen-induced hair damage. Androgens increase CXCL12 secretion through the androgen receptor (AR), affecting dermal papilla cells (DPCs) and inducing hair loss. Similarly, in AA models, CXCL12 expression rises, with αCXCL12 injections significantly inhibiting hair loss and reducing CD8+ MHC-I+ and MHC-II+ cell numbers in the skin. This suggests that CXCL12 plays a role in the progression of both AGA and AA, making αCXCL12 a promising candidate for hair loss treatment.
The findings offer a novel pathway for enhancing stem cell therapy efficacy, particularly for Novastem's treatments targeting AGA and AA. By modulating the CXCL12/CXCR4 axis, it's possible to improve stem cell recruitment and function at the injury site, potentially offering better outcomes for patients suffering from these hair loss conditions. This research aligns with the broader goals of regenerative medicine, seeking innovative solutions for conditions lacking effective treatments.
#CXCL12 #AndrogenicAlopecia #AlopeciaAreata #NeutralizingAntibody #StemCellTherapy #Novastem #HairLossTreatment